tolterodine-tartrate and Pulmonary-Disease--Chronic-Obstructive

This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of 'inhalation by design'. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.

Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Drug Design; Drug Therapy, Combination; Guinea Pigs; Molecular Structure; Muscarinic Antagonists; Phenylpropanolamine; Pulmonary Disease, Chronic Obstructive; Tolterodine Tartrate